Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY ICH Likely to OK Brazil, China as Assembly Members at Fukuoka Confab
May 26, 2015
-
BUSINESS Celgene Launches Multiple Myeloma Treatment Pomalyst; Keio Professor Acknowledges Its Efficacy in PFS, OS Improvement
May 26, 2015
-
BUSINESS Sales Increase 19.3% for 3 Generic-Only Makers; Incentive for DPC Hospitals Spurs Growth
May 25, 2015
-
TRENDS Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
May 22, 2015
-
BUSINESS Sales of SGLT-2 Inhibitors Were Sluggish in FY2014, but Expected to Pick Up with Lifting of 14-Day Prescription Limit
May 21, 2015
-
REGULATORY Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
-
BUSINESS Top 4 Drug Wholesalers Report 0.82% Operating Profit Rate in FY2014
May 20, 2015
-
BUSINESS Biogen Japan Sets to Quadruple Sales in 2 Years: New Chief
May 19, 2015
-
REGULATORY Panel OKs Sovaldi for Medical Subsidy, Monthly Copay at 10,000-20,000 Yen
May 19, 2015
-
BUSINESS Daiichi Sankyo Exits Global Hybrid Biz Model, Now Focuses on Innovation
May 18, 2015
-
REGULATORY PAFSC Second Committee to Discuss Gilead’s Combination Hepatitis C Treatment on May 28
May 15, 2015
-
REGULATORY Chuikyo Reps Discuss HTA, Re-Pricing as Sovaldi Lands in Japan
May 14, 2015
-
REGULATORY Sovaldi’s 5 Million Yen Price Tag OK’d for 12-Week Regimen, Listing on May 20
May 13, 2015
-
BUSINESS Ono to Expand Cancer-Specialized Rep Force to 150 by October Aiming for Additional Indications for Opdivo
May 13, 2015
-
BUSINESS Astellas Earnings Buoyant on Xtandi, Overseas Sales Offset Japan Fall
May 12, 2015
-
REGULATORY Chuikyo to Discuss Listing of Gilead’s Sovaldi on May 13; Listing Could Take Place This Month
May 11, 2015
-
REGULATORY 10-Year Reexamination Period Possible for Repositioned Drugs under Sakigake System: Official
May 8, 2015
-
ACADEMIA MHLW-Funded Study Calls for Use-Based Development Plans for Combination Drugs
May 7, 2015
-
BUSINESS Nichi-Iko Most Favored Maker of Plavix Generics: Survey
May 1, 2015
-
BUSINESS Daiichi Sankyo Cuts FY2014 Forecasts on Write-Off Loss Tied to Zelboraf
April 30, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…